{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:40:12Z","timestamp":1787917212134,"version":"build-2784847793"},"reference-count":24,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37 AI34495"],"award-info":[{"award-number":["R37 AI34495"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA065493"],"award-info":[{"award-number":["P01 CA065493"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA208398"],"award-info":[{"award-number":["R01 CA208398"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000885","name":"Children's Cancer Research Fund","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013187","name":"Randy Shaver Cancer Research and Community Fund","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100013187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011539","name":"Masonic Cancer Center, University of Minnesota","doi-asserted-by":"crossref","award":["Pre-R01 Award"],"award-info":[{"award-number":["Pre-R01 Award"]}],"id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be reduced if CAR T-cell activity was regulatable rather than constitutive. To test this, we compared the efficacies and morbidities of constitutively active (conventional) and regulatable (switchable) CAR (sCAR) T-cells specific for human CD19 (huCD19) in an immune-competent huCD19<jats:sup>+<\/jats:sup> transgenic mouse model.<\/jats:p>\n               <jats:p>Conventional CAR (CAR19) and sCAR T-cells were generated by retrovirally transducing C57BL\/6 (B6) congenic T-cells with constructs encoding antibody-derived single chain Fv (sFv) fragments specific for huCD19 or a peptide neoepitope (PNE), respectively. Transduced T-cells were adoptively transferred into huCD19 transgenic hemizygous (<jats:italic>huCD19<jats:sup>Tg\/0<\/jats:sup>\n                  <\/jats:italic>) B6 mice; healthy B-cells in these mice expressed <jats:italic>huCD19<jats:sup>Tg<\/jats:sup>\n                  <\/jats:italic>. Prior to transfer, recipients were treated with a lymphodepleting dose of cyclophosphamide to enhance T-cell engraftment. In tumor therapy experiments, CAR19 or sCAR T-cells were adoptively transferred into <jats:italic>huCD19<jats:sup>Tg\/0<\/jats:sup>\n                  <\/jats:italic> mice bearing a syngeneic B-cell lymphoma engineered to express huCD19. To regulate sCAR T cell function, a switch protein was generated that contained the sCAR-specific PNE genetically fused to an anti-huCD19 Fab fragment. Recipients of sCAR T-cells were injected with the switch to link sCAR effector with huCD19<jats:sup>+<\/jats:sup> target cells. Mice were monitored for survival, tumor burden (where appropriate), morbidity (as measured by weight loss and clinical scores), and peripheral blood lymphocyte frequency.<\/jats:p>\n               <jats:p>CAR19 and sCAR T-cells functioned comparably regarding in vivo expansion and B-cell depletion. However, sCAR T-cells were better tolerated as evidenced by the recipients\u2019 enhanced survival, reduced weight loss, and improved clinical scores. Discontinuing switch administration allowed healthy B-cell frequencies to return to pretreatment levels.<\/jats:p>\n               <jats:p>In our mouse model, sCAR T-cells killed huCD19<jats:sup>+<\/jats:sup> healthy and malignant B-cells and were better tolerated than CAR19 cells. Our data suggest sCAR might be clinically superior to the current FDA-approved therapies for B-cell lymphomas due to the reduced acute and chronic morbidities and mortality, lower incidence and severity of side effects, and B-cell reconstitution on cessation of switch administration.<\/jats:p>","DOI":"10.1136\/jitc-2022-005934","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T09:52:26Z","timestamp":1671097946000},"page":"e005934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19<sup>+<\/sup> malignancy"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-6554","authenticated-orcid":false,"given":"Christopher A","family":"Pennell","sequence":"first","affiliation":[{"name":"Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Campbell","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan D","family":"Storlie","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bolivar-Wagers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Osborn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Refaeli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Colorado Denver School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jensen","sequence":"additional","affiliation":[{"name":"Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Viaud","sequence":"additional","affiliation":[{"name":"Calibr, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis S","family":"Young","sequence":"additional","affiliation":[{"name":"Calibr, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R","family":"Blazar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2025100310523044000_10.12.e005934.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"2025100310523044000_10.12.e005934.2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100310523044000_10.12.e005934.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6"},{"key":"2025100310523044000_10.12.e005934.4","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100310523044000_10.12.e005934.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071"},{"key":"2025100310523044000_10.12.e005934.6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"2025100310523044000_10.12.e005934.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"2025100310523044000_10.12.e005934.8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"2025100310523044000_10.12.e005934.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"key":"2025100310523044000_10.12.e005934.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2025100310523044000_10.12.e005934.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524155113"},{"key":"2025100310523044000_10.12.e005934.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1810060115"},{"key":"2025100310523044000_10.12.e005934.13","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1002\/anie.201601902","article-title":"Design of switchable chimeric antigen receptor T cells targeting breast cancer","volume":"55","author":"Cao","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"2025100310523044000_10.12.e005934.14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316595"},{"key":"2025100310523044000_10.12.e005934.15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ymthe.2018.04.006","article-title":"Human CD19-Targeted mouse T cells induce B cell aplasia and toxicity in human CD19 transgenic mice","volume":"26","author":"Pennell","year":"2018","journal-title":"Mol Ther"},{"key":"2025100310523044000_10.12.e005934.16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.14.6.3884"},{"key":"2025100310523044000_10.12.e005934.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060152"},{"key":"2025100310523044000_10.12.e005934.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337360"},{"key":"2025100310523044000_10.12.e005934.19","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"2025100310523044000_10.12.e005934.20","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"2025100310523044000_10.12.e005934.21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"2025100310523044000_10.12.e005934.22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"2025100310523044000_10.12.e005934.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1855"},{"key":"2025100310523044000_10.12.e005934.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:52:37Z","timestamp":1759513957000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/jitc-2022-005934"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005934","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}